DXCM · Dexcom Inc
Price
Snapshot
50 fields · last close| Market Cap | $33.85B |
| P/E | 33.86 |
| Float | 375.9M |
| Beta | 1.45 |
| Volatility | 36.3% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 73 |
| Price | 88.20 |
| Change | −1.68% |
| Prev Close | 89.71 |
| Open | 89.73 |
| Day Low | 89.05 |
| Day High | 91.00 |
| Avg Vol | 3 |
| Avg $ Vol | $302.0M |
| 52W High | 92.59 |
| 52W Low | 54.11 |
| 52W Pos | 88.6% |
| From High | −4.74% |
| From Low | +63.00% |
| Max DD 1Y | −31.88% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.71% |
| SMA 50 | +9.11% |
| SMA 200 | +24.63% |
| RSI (14) | 59.3 |
| Vol 30D | 43.0% |
| Vol 90D | 43.9% |
| 1Y Range | 54–93 |
| Daily bars | 507 |
| Perf Week | +0.47% |
| Perf Month | +8.53% |
| Perf Quarter | +23.58% |
| Perf Half Y | +31.73% |
| Perf Year | +11.08% |
| Perf YTD | +32.55% |
| Prev Day | −1.68% |
| Clavix | B |
| Debt / Eq | 0.00 |
| Curr Ratio | 1.88 |
| Int Cover | 32.4× |
| FCF Margin | 23.1% |
| Rev Growth | +0.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 28 / 47 |
What DXCM does
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Clavix risk grade
regraded every trading dayDXCM grades B, 73 of 100. Steadiest on Sector Resilience (72), most exposed on Price Stability (53, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 28 of 47 in Health Care by Clavix score.
How rough the ride is
| DXCM | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.45 | 0.81 |
| Volatilityannualized | 36.3% | 20.4% |
| Max drawdown, past yearworst peak-to-trough fall | −31.9% | — |
| Typical daily movemedian absolute daily change | 1.32% | — |
| Days beyond ±3%of the last 252 sessions | 4317% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| DXCM | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.45 | 0.81 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| DXCM | |
|---|---|
| 1 week | +0.5% |
| 1 month | +8.5% |
| Year to date | +32.6% |
| 1 year | +11.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| DXCM | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 30 Jul |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 2 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| DXCM | |
|---|---|
| Revenue growthyear over year | +0.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Health Care
47 companies| Metric | DXCM | Sector spread | Median |
|---|---|---|---|
| Beta | 1.45 | 0.81 | |
| Volatility | 36.3% | 20.4% | |
| P/E | 33.86 | 26.14 | |
| Debt / equity | 0.00 | 0.71 | |
| Current ratio | 1.88 | 1.58 | |
| FCF margin | 23.1% | 8.6% | |
| Interest coverage | 32.4× | 6.3× |
Recent news
most recent scored articles · the chip is the article’s score · click to openWall Street Zen lowered its rating on DexCom (DXCM) from 'buy' to 'hold' in a report issued on Saturday. No further details or reasons were provided in the article.
DexCom EVP Sadie Stern sold 2,565 shares on August 27 at an average price of $88.37, totaling about $226,669, reducing her position by roughly 1.99%. After the sale she still held 126,043 shares worth about $11.1 million.
Bank of Nova Scotia disclosed that it opened a new position in DexCom during the second quarter, buying 1,266,285 shares of the medical device company in an SEC filing.
DexCom stock is up 33.4% year to date, but a valuation analysis using a Discounted Cash Flow (DCF) model, which estimates what a company is worth based on the cash it is expected to generate in the future, suggests the shares may be trading at a 37% discount to that estimate. The article notes the overall value score leans less generous, describing the picture as mixed.
Analysts nudged their price target for DexCom from US$91.64 to US$94.12, while commentary around the stock was mixed, weighing positive Q2 2026 results, new clinical data and updated guidance against ongoing questions about valuation and sector sentiment.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| CNC | Centene Corp | B | $33.60B | — | 1.08 | Compare |
| VEEV | Veeva Systems Inc | B- | $34.18B | 45.52 | 0.91 | Compare |
| RMD | Resmed Inc | B+ | $33.06B | 21.74 | 0.77 | Compare |
| GEHC | GE Healthcare Technologies Inc | B- | $31.49B | 16.79 | 0.82 | Compare |
| ALC | Alcon AG | B+ | $29.66B | 44.75 | 1.12 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $41.70B | 36.69 | 1.57 | Compare |
| LH | Labcorp Holdings Inc | A- | $26.88B | 26.91 | 0.88 | Compare |
| DGX | Quest Diagnostics Inc | A- | $26.42B | 24.97 | 0.56 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.